Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

@article{Sevigny2015AducanumabA,
  title={Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study},
  author={Jeff Sevigny and Ping Chiao and Leslie Williams and Tianle Chen and Yan Ling and John O’Gorman and Christoph Hock and Roger M. Nitsch and Alfred W. Sandrock},
  journal={Alzheimer's \& Dementia},
  year={2015},
  volume={11}
}

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

A critically review the growing body of evidence supporting the monitoring of CSF anti-Aβ autoantibody as a promising candidate biomarker for ARIA in clinical trials.

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Control studies regarding prevention and treatment of ARIA are lacking, but anecdotal evidence suggests that a pulse of intravenous corticosteroids may be of benefit, as well as a course of anticonvulsant for seizures.

Developing therapeutic vaccines against Alzheimer’s disease

Greater therapeutic efficacy for the next generation of vaccine approaches will likely benefit from specifically targeting the most toxic species of Aβ and tau, ideally simultaneously.

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

Given the clinical therapeutic effects of anti‐Aβ immunotherapies for AD, aducanumab and solanezumab improve the cognitive function, while aducanical and bapineuzumab may increase the risks of ARIA.

Recent advancements toward therapeutic vaccines against Alzheimer’s disease

This review covers the more recent advances in vaccine development for AD from 2016 to present and concludes that greatest clinical efficacy will most likely be achieved by concurrently targeting the most toxic forms of both Aβ and tau.

Targeting microglia for the treatment of Alzheimer's Disease

The considerations in selecting microglial therapeutic targets from the perspective of drug discovery feasibility are discussed, and the role of microglia in ongoing immunotherapy clinical strategies is considered.

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

This commentary focuses on the prophylactic immunotherapy of Alzheimer's disease using recombinant Aβ B-cell epitope chimeric protein as subunit vaccine targeting amyloid-β, and discusses the efficiency and perspective of this type of recombinant subunit protein vaccine.

Emerging amyloid and tau targeting treatments for Alzheimer’s disease

There is a significant need for further research targeting the disease at an earlier stage and progress in biomarker and imaging technology are improving the outlook, allowing development of effective targeted treatments.